CalciMedica, Inc. (NASDAQ:CALC - Get Free Report) Director Fred A. Middleton acquired 4,800 shares of the business's stock in a transaction on Friday, December 6th. The shares were bought at an average cost of $2.65 per share, with a total value of $12,720.00. Following the completion of the acquisition, the director now owns 36,514 shares in the company, valued at approximately $96,762.10. This represents a 15.14 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
CalciMedica Price Performance
CALC stock opened at $2.86 on Friday. The firm has a fifty day moving average price of $3.72 and a 200 day moving average price of $4.31. CalciMedica, Inc. has a fifty-two week low of $2.05 and a fifty-two week high of $8.38.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of CalciMedica in a report on Thursday, November 14th.
Get Our Latest Report on CALC
Institutional Inflows and Outflows
Did You See Trump’s Bombshell Exec. Order 001?
From Banyan Hill Publishing | Ad
Starting with what I call Exec. Order 001.
It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...
I put all the details together for you here — but please hurry.
Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in CalciMedica by 51.2% in the third quarter. Geode Capital Management LLC now owns 66,553 shares of the company's stock worth $295,000 after buying an additional 22,525 shares during the last quarter. Atria Investments Inc lifted its position in CalciMedica by 136.5% in the third quarter. Atria Investments Inc now owns 26,503 shares of the company's stock worth $117,000 after buying an additional 15,296 shares during the last quarter. Finally, PVG Asset Management Corp bought a new stake in CalciMedica in the third quarter worth $67,000.
CalciMedica Company Profile
(
Get Free Report)
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
